Oak Ridge Investments LLC Sells 2,740 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Oak Ridge Investments LLC reduced its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 5.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,599 shares of the company’s stock after selling 2,740 shares during the quarter. Oak Ridge Investments LLC owned approximately 0.07% of Travere Therapeutics worth $916,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. CWM LLC lifted its position in shares of Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares during the last quarter. DRW Securities LLC acquired a new stake in Travere Therapeutics during the 2nd quarter worth about $95,000. Quarry LP purchased a new position in Travere Therapeutics during the third quarter valued at approximately $105,000. Forefront Analytics LLC increased its holdings in shares of Travere Therapeutics by 10.2% during the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after purchasing an additional 1,237 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Travere Therapeutics in the second quarter worth about $117,000.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TVTX shares. Barclays boosted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $27.00 in a research note on Monday, October 21st. Cantor Fitzgerald assumed coverage on Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating on the stock. Wedbush increased their price target on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Finally, Citigroup reduced their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, September 27th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.00.

Insiders Place Their Bets

In related news, CAO Sandra Calvin sold 15,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jula Inrig sold 2,066 shares of Travere Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $19.10, for a total value of $39,460.60. Following the sale, the insider now directly owns 59,883 shares of the company’s stock, valued at $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,596 shares of company stock worth $527,262 in the last quarter. 4.06% of the stock is owned by company insiders.

Travere Therapeutics Stock Down 0.5 %

Shares of TVTX opened at $18.37 on Monday. The company’s 50-day simple moving average is $18.21 and its 200-day simple moving average is $14.56. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $20.33. The stock has a market capitalization of $1.43 billion, a PE ratio of -4.04 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.01. The company had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm’s revenue was up 69.6% compared to the same quarter last year. During the same quarter last year, the company posted ($1.17) EPS. Analysts forecast that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.